drugset / Trial / NCT00493610
Mucomyst for Hepatitis C
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study will examine the effects of treatment with N-acetylcysteine ( Mucomyst ) 1 gm twice a day for 30 dyas in 15 patients with hepatitis C. The primary outcome of interest wil be the changes in oxidant stress as measured by different oxidant stress markers level in sera. Secondary outcomes of interest will be changes in viral load of hep C and changes in liver function
Timeline
- Start
- 2006-11
- Primary completion
- 2008-06
- Completion
- 2008-06
Outcome
Outcome not reported
Stopped (Business): “Collaborator no longer interested, short of funds”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 1000 mg | Oral |